Treatment Protocols
The risk classification for advanced seminoma testicular cancer is presented below, followed by the treatment protocols for seminoma testicular cancer, including treatment by clinical stages and treatment recommendations for second-line therapy and for persistent or recurrent disease.
Risk classification for advanced seminoma testicular cancer
The International Germ Cell Cancer Consensus Group (IGCCCG) developed a classification system based on identifying clinically independent prognostic features, including extent of disease and levels of serum tumor markers. In testicular cancer post-orchiectomy, markers are used to determine risk classification.
Good-risk seminoma:
Any primary site
No nonpulmonary visceral metastases
Intermediate-risk seminoma:
Any primary site
Nonpulmonary visceral metastases
Poor-risk seminoma:
No patients are classified as poor risk
Treatment recommendations for stage I seminoma testicular cancer
Stages IA and IB:
Radical inguinal orchiectomy is considered the primary treatment for most patients who present with a suspicious testicular mass; pathologic diagnosis may show pure seminoma or nonseminoma germ cell tumors
Primary treatment for pure seminoma includes surveillance, radiotherapy, and chemotherapy
Radical inguinal orchiectomy followed by adjuvant radiation therapy; adjuvant radiation at 20-25 Gy to the infradiaphragmatic area, including the para-aortic and ipsilateral ilioinguinal nodes
or
Radical inguinal orchiectomy can be followed by adjuvant chemotherapy with carboplatin AUC 7 for one or two cycles; single-dose carboplatin is less toxic and just as effective as adjuvant radiotherapy after orchiectomy
Stage IS:
Generally, treatment for stage IS involves radiation therapy with radiation to the infradiaphragmatic area, including the para-aortic lymph nodes with or without radiation to the ipsilateral ilioinguinal nodes
Radiation therapy can be given at a dose of 20 Gy preferred or 25 Gy
Treatment recommendations for stage II seminoma testicular cancer
Stages IIA and IIB:
Primary treatment includes radiation therapy to the infradiaphragmatic area, including the para-aortic lymph nodes, with radiation to the ipsilateral iliac area; accepted radiation dose is 30-35 Gy
Chemotherapy may be used for patients with stage IIB; consider four cycles of etoposide and cisplatin (EP) or three cycles of bleomycin, etoposide, and cisplatin (BEP) as alternatives to radiotherapy
Chemotherapy treatment recommendations for stage IIB disease:
EP regimen for four cycles: Etoposide 100 mg/m2 IV on days 1-5 plus cisplatin 20 mg/m2 IV on days 1-5; every 21d
or
BEP regimen for three cycles: Etoposide 100 mg/m2 IV on days 1-5 plus cisplatin 20 mg/m2 IV on days 1-5 plus bleomycin 30 U IV weekly on days 1, 8, and 15; every 21d
Stages IIC and III:
Patients with stage II or III seminoma are considered to have good risk, with the exception of patients who have stage III disease with nonpulmonary visceral metastases, who are classified as intermediate-risk patients.
Good-risk seminoma: Primary chemotherapy:
EP regimen for four cycles: Etoposide 100 mg/m2 IV on days 1-5 plus cisplatin 20 mg/m2 IV on days 1-5; every 21d
or
BEP regimen for three cycles: Etoposide 100 mg/m2 IV on days 1-5 plus cisplatin 20 mg/m2 IV on days 1-5 plus bleomycin 30 U IV weekly on days 1, 8, and 15; every 21d
Intermediate-risk seminoma: Primary chemotherapy:
BEP regimen for four cycles: Etoposide 100 mg/m2 IV on days 1-5 plus cisplatin 20 mg/m2 IV on days 1-5 plus bleomycin 30 U IV weekly on days 1, 8, and 15; every 21d
VIP for four cycles is another option, but BEP is preferred.
Second-line treatment recommendations
VeIP (vinblastine, ifosfamide, and cisplatin) regimen
:
Vinblastine 0.11 mg/kg IV push on days 1-2 plus ifosfamide 1200 mg/m2 IV daily on days 1-5 plus mesna 400 mg/m2 IV infused over 30 min before ifosfamide, then 4h and 8h after the start of ifosfamide on days 1-5 plus cisplatin (CDDP) 20 mg/m2 IV on days 1-5; every 21d for 4 cycles
TIP (paclitaxel, ifosfamide, and cisplatin) regimen
:
Paclitaxel 250 mg/m2 IV on day 1 plus ifosfamide 1500 mg/m2 IV on days 2-5 plus cisplatin (CDDP) 25 mg/m2 IV on days 2-5 plus mesna 500 mg/m2 IV infused over 30 min before ifosfamide, then at 4h and 8h after each dose of ifosfamide on days 2-5; every 21d for 4 cycles
VIP (etoposide, ifosfamide, and cisplatin) regimen
:
Etoposide (VP-16) 75 mg/m2 IV infused over 1h on days 1-5 plus ifosfamide 1200 mg/m2 IV infused over 3h on days 1-5 plus cisplatin (CDDP) 20 mg/m2 IV infused over 1h on days 1-5 plus mesna 400 mg/m2 IV over 30 min before ifosfamide and then 4h and 8h after the start of each ifosfamide dose on days 1-5; every 21d
Persistent or recurrent disease treatment recommendations
Patients who have persistent or recurrent disease should be given palliative chemotherapy that includes gemcitabine and oxaliplatin.
GEMOX (gemcitabine plus oxaliplatin) regimen
:
Gemcitabine 1000-1250 mg/m2 IV infused over 30 min on days 1 and 8 followed by oxaliplatin 130 mg/m2 IV infused over 2h on day 1; every 21d